30.44
0.24 (0.79%)
| Previous Close | 30.20 |
| Open | 30.45 |
| Volume | 360,727 |
| Avg. Volume (3M) | 367,919 |
| Market Cap | 978,408,576 |
| Price / Earnings (TTM) | 24.95 |
| Price / Earnings (Forward) | 4.36 |
| Price / Sales | 1.72 |
| Price / Book | 4.09 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Profit Margin | 6.61% |
| Operating Margin (TTM) | 13.71% |
| Diluted EPS (TTM) | 1.22 |
| Quarterly Revenue Growth (YOY) | 22.70% |
| Quarterly Earnings Growth (YOY) | -91.30% |
| Total Debt/Equity (MRQ) | 411.94% |
| Current Ratio (MRQ) | 1.08 |
| Operating Cash Flow (TTM) | 198.44 M |
| Levered Free Cash Flow (TTM) | 341.32 M |
| Return on Assets (TTM) | 7.95% |
| Return on Equity (TTM) | 19.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bearish | Mixed | |
| Stock | Collegium Pharmaceutical, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 0.5 |
| Average | 1.75 |
|
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 1.69% |
| % Held by Institutions | 117.12% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (HC Wainwright & Co., 64.26%) | Buy |
| Median | 46.00 (51.12%) | |
| Low | 37.00 (Piper Sandler, 21.55%) | Hold |
| Average | 44.33 (45.63%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 28.61 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 09 May 2025 | 37.00 (21.55%) | Hold | 28.89 |
| Needham | 09 Apr 2025 | 46.00 (51.12%) | Buy | 26.37 |
| HC Wainwright & Co. | 24 Mar 2025 | 50.00 (64.26%) | Buy | 30.56 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 May 2025 | Announcement | Collegium to Participate in Upcoming Investor Conferences |
| 12 May 2025 | Announcement | Collegium Announces $25 Million Accelerated Share Repurchase Program |
| 08 May 2025 | Announcement | Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress |
| 24 Apr 2025 | Announcement | Collegium to Report First Quarter 2025 Financial Results on May 8, 2025 |
| 01 Apr 2025 | Announcement | Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference |
| 27 Mar 2025 | Announcement | Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |